Skip to main content
women with smiling face in lab coat with head cap.


Our focus

A broad range of technologies for diagnosing and treating heart rhythm disorders.

Mary's story

Our EP portfolio is centered on delivering meaningful innovation for diagnosing and treating heart rhythm disorders, improving safety for patients, and improving efficiency for physicians.

Delivering meaningful innovation

Redefining heart care.

We’re dedicated to helping patients live longer, healthier lives with the RHYTHMIA HDx™ Mapping System, which provides physicians the ability to diagnose arrhythmias with greater efficiency, deliver targeted therapy and confidently achieve procedural endpoints in complex substrates. The DIRECTSENSE™ Technology adds support, measuring local impedance to provide insights into tissue characteristics and deepening the understanding of how lesions will form during ablation. 

The future of ablation.

Advancements in treating atrial arrhythmias have given physicians more therapeutic options. The FARAPULSE™ Pulsed Field Ablation (PFA) System* is the pioneer of PFA – a novel, non-thermal method for cardiac ablation, which uses a process called irreversible electroporation designed to precisely and efficiently ablate cardiac tissue, while preserving adjacent tissue. The POLARx™ Cryoablation System* incorporates physician-driven design changes to provide increased procedural predictability in the treatment of paroxysmal atrial fibrillation.

Access better outcomes. 

Our transseptal crossing platforms facilitate predictable and safe left heart access by using radiofrequency (RF) energy – a method shown to increase efficiency and improve the safety and efficacy of transseptal puncture during left heart procedures.i,ii,iii The VersaCross™ RF Transseptal Solution streamlines these crossing procedures and therapy delivery by eliminating potential wire and sheath exchanges, which may help mitigate risks during procedures.

i Journal of the American Heart Association, September 17, 2003. DOI: 10.1161/JAHA. 113000428

ii Winkle et al. Heart Rhythm, Vol. 8, Issue 9, 2022. DOI 10.1016/j.hrthm.2011.04.032

iii Inohara et al. J Interv Card Electrophys, 2021; in press (DOI: 10.1007/s10840-020-00931-7)

check icon

VersaCross: 2X faster LAAC sheath delivery compared to conventional mechanical needle.1

check icon

RHYTHMIA HDx: 25X more data than conventional mapping system.2

check icon

FARAPULSE: First commercialized PFA technology.


Approximately 89% of all ablation cases worldwide are done with aid of mapping and navigation.3


An estimated 400K electrophysiology ablation procedures were performed in the US in 2019.4


More than 700K transseptal procedures are performed globally every year.5

Conditions we treat

  • Cardiac Arrhythmias

Solutions we offer

  • Radiofrequency ablation
  • Pulsed field ablation
  • Cryoablation
  • Left heart access systems
  • Cardiac ablation catheters
  • Mapping equipment

Product spotlights


  3. The ratio is calculated from Decision Resources Group. Source: DRG’s Medtech 360 Reports on Electrophysiology Mapping and Ablation Devices in Europe, LATAM, APAC and US (
  4. 2019 estimate from Decision Resources Group. Source: DRG’s Medtech 360 Report on Electrophysiology Mapping and Ablation Devices, US, June 2019. (
  5. Source: MRG, Clarivate, internal data on file
  6. Reddy VY, Neuzil P, Koruth JS, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019;74(3):315-326. doi:10.1016/j.jacc.2019.04.021
  7. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444. doi:10.1016/j.hrthm.2017.05.012

*In the U.S., the FARAPULSE PFA System and the POLARx Cryoablation System are investigational devices and not available for sale.